指南与共识胸部肿瘤支持与姑息治疗

新USPSTF推荐下肺癌筛查与戒烟干预联合的影响

Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force.
指南 / 共识 · J Thorac Oncol · 2021-10-12

结果显示,2021标准下30%覆盖率不联合戒烟可避免6845例肺癌死亡、获得103725生命年,较2013标准分别增加28%和34%;联合15%有效性戒烟干预可额外避免2422例死亡(总计9267例,较2013标准30%覆盖率不联合戒烟增加约73%)并获得322785生命年(增加约318%)。结论认为联合筛查与戒烟干预可大幅减少肺癌死亡并增加生命年,将戒烟项目纳入筛查实践应作为优先事项。

要点

  • 2021 USPSTF标准下30%筛查覆盖率不联合戒烟,较2013标准增加28%肺癌死亡避免和34%生命年。
  • 筛查时联合15%有效性戒烟干预,额外避免2422例肺癌死亡,生命年增至322785(增约318%)。
  • 100%筛查覆盖率联合15%戒烟干预可避免31998例肺癌死亡,获得1086840生命年(增约1309%)。

核心结论

  • 联合筛查与戒烟干预可大幅减少肺癌死亡并增加生命年。
  • 一次15%有效性的戒烟干预带来的生命年增益与将筛查覆盖率从30%提高至100%相当。

研究设计与样本

  • 使用经过验证的肺癌自然史模型进行模拟研究。
  • 比较USPSTF 2013与2021筛查标准,筛查覆盖率设为0%、30%、100%,联合或不联合筛查时戒烟干预(有效性15%或100%)。

主要发现

  • 2021标准30%覆盖率不联合戒烟:避免6845例肺癌死亡,获得103725生命年,较2013标准分别增加28%和34%。
  • 2021标准30%覆盖率联合15%有效性戒烟:避免9267例肺癌死亡(较2013标准30%覆盖率不联合戒烟增加约73%),获得322785生命年(增加约318%)。
  • 2021标准100%覆盖率不联合戒烟:避免23444例肺癌死亡(增加约337%),获得354330生命年(增加约359%)。
  • 2021标准100%覆盖率联合15%有效性戒烟:避免31998例肺癌死亡(增加约497%),获得1086840生命年(增加约1309%)。

临床怎么用

  • 在肺癌筛查实践中应优先整合戒烟干预项目,以最大化总体获益。
  • 即使戒烟干预有效性仅为15%,其带来的生命年增益也可与大幅提高筛查覆盖率相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2021, the U.S. Preventive Services Task Force (USPSTF) revised its lung cancer screening recommendations expanding its eligibility. As more smokers become eligible, cessation interventions at the point of screening could enhance the benefits. Here, we evaluate the effects of joint screening and cessation interventions under the new recommendations. METHODS: A validated lung cancer natural history model was used to estimate lifetime number of low-dose computed tomography screens, percentage ever screened, lung cancer deaths, lung cancer deaths averted, and life-years gained for the 1960 U.S. birth cohort aged 45 to 90 years (4.5 million individuals). Screening occurred according to the USPSTF 2013 and 2021 recommendations with varying uptake (0%, 30%, 100%), with or without a cessation intervention at the point of screening with varying effectiveness (15%, 100%). RESULTS: Screening 30% of the eligible population according to the 2021 criteria with no cessation intervention (USPSTF 2021, 30% uptake, without cessation intervention) was estimated to result in 6845 lung cancer deaths averted and 103,725 life-years gained. These represent 28% and 34% increases, respectively, relative to screening according to the 2013 guidelines (USPSTF 2013, 30% uptake, without cessation intervention). Adding a cessation intervention at the time of the first screen with 15% effectiveness (USPSTF 2021, 30% uptake, with cessation intervention with 15% effectiveness) was estimated to result in 2422 additional lung cancer deaths averted (9267 total, ∼73% increase versus USPSTF 2013, 30% uptake, without cessation intervention) and 322,785 life-years gained (∼318% increase). Screening 100% of the eligible according to the 2021 guidelines with no cessation intervention (USPSTF 2021, 100% uptake, without cessation intervention) was estimated to result in 23,444 lung cancer deaths averted (∼337% increase versus USPSTF 2013, 30% uptake, without cessation intervention) and 354,330 life-years gained (∼359% increase). Adding a cessation intervention with 15% effectiveness (USPSTF 2021, 100% uptake, with cessation intervention with 15% effectiveness) would result in 31,998 lung cancer deaths averted (∼497% increase versus USPSTF 2013, 30% uptake, without cessation intervention) and 1,086,840 life-years gained (∼1309% increase). CONCLUSIONS: Joint screening and cessation interventions would result in considerable lung cancer deaths averted and life-years gained. Adding a one-time cessation intervention of modest effectiveness (15%) results in comparable life-years gained as increasing screening uptake from 30% to 100% because while cessation decreases mortality from many causes, screening only reduces lung cancer mortality. This simulation indicates that incorporating cessation programs into screening practice should be a priority as it can maximize overall benefits.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Meza R, Cao P, Jeon J, et al. Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force. J Thorac Oncol. 2021. PMID: 34648947. doi:10.1016/j.jtho.2021.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。